Literature DB >> 16542653

Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656.

John M Ridley1, James T Milnes, Rona S Duncan, Mark J McPate, Andrew F James, Harry J Witchel, Jules C Hancox.   

Abstract

The mechanism of human ether-à-go-go-related gene (HERG) K+ channel blockade by the antifungal agent ketoconazole was investigated using patch-clamp recording from mammalian cell lines. Ketoconazole inhibited whole-cell HERG current (IHERG) with a clinically relevant half-maximal inhibitory drug concentration (IC50) value of 1.7 microM. The voltage- and time-dependent characteristics of IHERG blockade by ketoconazole indicated dependence of block on channel gating, ruling out a significant role for closed-state channel inhibition. The S6 HERG mutations Y652A and F656A produced approximately 4-fold and approximately 21-fold increases in IC50 for IHERG blockade, respectively. Thus, ketoconazole accesses the HERG channel pore-cavity on channel gating, and the S6 residue F656 is an important determinant of ketoconazole binding.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16542653     DOI: 10.1016/j.febslet.2006.02.073

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  Transfer of rolf S3-S4 linker to HERG eliminates activation gating but spares inactivation.

Authors:  Frank S Choveau; Aziza El Harchi; Nicolas Rodriguez; Bénédicte Louérat-Oriou; Isabelle Baró; Sophie Demolombe; Flavien Charpentier; Gildas Loussouarn
Journal:  Biophys J       Date:  2009-09-02       Impact factor: 4.033

2.  Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride.

Authors:  Yan Long; Zuoxian Lin; Menghang Xia; Wei Zheng; Zhiyuan Li
Journal:  Toxicol Appl Pharmacol       Date:  2013-01-08       Impact factor: 4.219

3.  Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome.

Authors:  H Takemasa; T Nagatomo; H Abe; K Kawakami; T Igarashi; T Tsurugi; N Kabashima; M Tamura; M Okazaki; B P Delisle; C T January; Y Otsuji
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

4.  Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon?

Authors:  M A G van der Heyden; M E Smits; M A Vos
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

5.  Torsades de Pointes ventricular tachycardia in a pediatric patient treated with fluconazole.

Authors:  Jesse J Esch; Michal J Kantoch
Journal:  Pediatr Cardiol       Date:  2007-09-12       Impact factor: 1.655

6.  Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information.

Authors:  H Mishra; S Polak; M Jamei; A Rostami-Hodjegan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-08-13

Review 7.  The Role of Interaction Model in Simulation of Drug Interactions and QT Prolongation.

Authors:  Barbara Wiśniowska; Sebastian Polak
Journal:  Curr Pharmacol Rep       Date:  2016-10-27

8.  Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.

Authors:  R S Duncan; M J McPate; J M Ridley; Z Gao; A F James; D J Leishman; J L Leaney; H J Witchel; J C Hancox
Journal:  Biochem Pharmacol       Date:  2007-05-03       Impact factor: 5.858

9.  The macrolide drug erythromycin does not protect the hERG channel from inhibition by thioridazine and terfenadine.

Authors:  Aziza El Harchi; Andrew S Butler; Yihong Zhang; Christopher E Dempsey; Jules C Hancox
Journal:  Physiol Rep       Date:  2020-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.